These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20204306)

  • 1. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
    Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
    Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
    Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
    Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
    Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
    Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
    Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.
    Lee KH; Hur HS; Im SA; Lee J; Kim HP; Yoon YK; Han SW; Song SH; Oh DY; Kim TY; Bang YJ
    Cancer Lett; 2010 Dec; 299(1):22-8. PubMed ID: 20727673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
    Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
    Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
    Zatelli MC; Minoia M; Martini C; Tagliati F; Ambrosio MR; Schiavon M; Buratto M; Calabrese F; Gentilin E; Cavallesco G; Berdondini L; Rea F; degli Uberti EC
    Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
    Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.
    Zakikhani M; Blouin MJ; Piura E; Pollak MN
    Breast Cancer Res Treat; 2010 Aug; 123(1):271-9. PubMed ID: 20135346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
    Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of mTOR siRNA on mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cells and the growth of transplanted tumor in nude mice].
    Liu MY; Hou GQ; Zhang Y; Bei WJ; Yan AH
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):334-9. PubMed ID: 21875460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX; Yang X; Sreejayan N; Ren J
    Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.